Table 1. Summary of Previous Cases of ICIs for Cancers With LEMS.
| Authors (year) | Age/sex | Cancer | ICIs | LEMS treatment | Anti-P/Q-type VGCC antibody (pmol/L) |
Outcomes |
||
|---|---|---|---|---|---|---|---|---|
| Pre-ICIs | Post-ICIs | LEMS | Cancer | |||||
| Dohrn et al, 2020 [10] | 62/F | MCC | Avelumab | 3,4-DAP + pyridostigmine | 387.6 | NA | Exacerbated | CR |
| Sakaguchi et al, 2022 [8] | 56/M | SCLC | Atezolizumab | None | > 30 | NA | Improved | PD (5 mo) |
| Takigawa et al, 2022 [7] | 73/F | Lung SQ | Pembrolizumab | IVIG | 124.9 | NA | Recurred | PR |
| Green et al, 2022 [9] | 67/M | MCC | Avelumab | 3,4-DAP + pyridostigmine | Undetectable | NA | Improved | PR |
| Ours | 62/F | SCLC | Durvalumab | Pyridostigmine | 1,419.2 | 263.4 | Improved | PD (5 mo) |
CR: complete remission; 3,4-DAP: 3,4-diaminopyridine; ICI: immune checkpoint inhibitor; IVIG: intravenous immunoglobulin; LEMS: Lambert-Eaton myasthenic syndrome; MCC: Merkel cell carcinoma; mo: months; NA: not assessed; PD: progressive disease; PR: partial response; SCLC: small-cell lung cancer: SQ: squamous cell carcinoma.